Markets:

Overview

News

Currencies

International

Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

47.70 +2.16 (+4.75%)

Streaming Delayed Price Updated: 11:53 AM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case ↗

January 07, 2026

Via Chartmill

3 Russell 2000 Stocks Walking a Fine Line

January 06, 2026

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...

Via StockStory

2 Reasons to Avoid COLL and 1 Stock to Buy Instead

December 28, 2025

Collegium Pharmaceutical has been on fire lately. In the past six months alone, the company’s stock price has rocketed 68.7%, setting a new 52-week high of $49.89 per share. This was partly thanks to...

Via StockStory

Topics Supply Chain

3 Cash-Producing Stocks We Think Twice About

December 23, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Collegium Pharmaceutical Inc (NASDAQ:COLL) Shows Strong Earnings Momentum and Bullish Technical Setup ↗

December 20, 2025

Collegium Pharmaceutical (COLL) shows strong earnings growth and a bullish technical setup, offering a potential breakout opportunity for momentum investors.

Via Chartmill

3 Unpopular Stocks We Find Risky

December 18, 2025

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

Collegium Pharmaceutical Inc (NASDAQ:COLL) Fits the Minervini Growth Momentum Strategy ↗

December 18, 2025

Collegium Pharmaceutical (COLL) aligns with Mark Minervini's SEPA strategy, showing a strong technical uptrend and robust fundamental earnings and sales growth.

Via Chartmill

Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)

December 14, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Growth Stock Set to Flourishand 2 Facing Challenges

December 11, 2025

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Via StockStory

1 Mooning Stock with Promising Prospects and 2 Facing Challenges

December 05, 2025

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Via StockStory

1 Small-Cap Stock with Exciting Potential and 2 We Avoid

November 23, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

Branded Pharmaceuticals Stocks Q3 Earnings: Eli Lilly (NYSE:LLY) Best of the Bunch

November 17, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Eli Lilly (NYSE:LLY) and the...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Collegium Pharmaceutical Inc (NASDAQ:COLL) Shows High Growth Momentum with Strong Technicals ↗

November 13, 2025

Discover how Collegium Pharmaceutical (COLL) combines a strong technical uptrend with powerful earnings growth, marking it as a high-potential stock.

Via Chartmill

5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q3 Earnings Call

November 13, 2025

Collegium Pharmaceutical’s third quarter was marked by robust demand for its ADHD medication Jornay PM and continued resilience in its pain management portfolio. Management pointed to a successful...

Via StockStory

Topics Earnings

1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off

November 12, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

2 Momentum Stocks with Exciting Potential and 1 We Find Risky

November 10, 2025

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage...

Via StockStory

Topics Credit Cards

COLL Q3 Deep Dive: Jornay PM Momentum and Pain Portfolio Drive Upgraded Outlook

November 07, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 31.4% year on year to $209.4 million. The company’s full-year revenue...

Via StockStory

Why Are Collegium Pharmaceutical (COLL) Shares Soaring Today

November 06, 2025

Shares of pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) jumped 11.6% in the morning session after the company reported strong third-quarter 2025 financial results, beating analyst...

Via StockStory

Topics Economy Government World Trade

Collegium Pharmaceutical Inc (NASDAQ:COLL) Beats Q3 2025 Estimates and Raises Full-Year Guidance ↗

November 06, 2025

Collegium Pharmaceutical (COLL) beat Q3 2025 earnings estimates and raised its full-year guidance, driven by strong performance in its pain and ADHD portfolios.

Via Chartmill

Collegium Pharmaceutical (NASDAQ:COLL) Delivers Impressive Q3, Stock Jumps 12.1%

November 06, 2025

Via StockStory

Earnings To Watch: Collegium Pharmaceutical (COLL) Reports Q3 Results Tomorrow

November 04, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors should know.

Via StockStory

3 Stocks Under $50 That Fall Short

October 31, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

Topics Artificial Intelligence

Collegium Pharmaceutical (COLL): Buy, Sell, or Hold Post Q2 Earnings?

October 23, 2025

Collegium Pharmaceutical has had an impressive run over the past six months as its shares have beaten the S&P 500 by 10%. The stock now trades at $35.02, marking a 34.7% gain. This was partly thanks to...

Via StockStory

Topics Stocks Supply Chain

UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know

October 10, 2025

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.

Via StockStory

Topics Economy Government World Trade

1 Russell 2000 Stock to Research Further and 2 We Avoid

September 26, 2025

Via StockStory

Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL)

September 24, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Safe-and-Steady Stock to Keep an Eye On and 2 Facing Headwinds

September 12, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

1 Stock Under $50 Worth Investigating and 2 We Ignore

August 13, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

Via StockStory

3 Profitable Stocks We Think Twice About

August 12, 2025

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.